A groundbreaking study from researchers at Kyoto University's Center for iPS Cell Research and Application (CiRA) has introduced a novel pluripotent stem cell-derived organoid model that faithfully recapitulates the development of the human adrenal cortex. Published in early April 2026 to coincide with the new academic year in Japan, this work marks a significant milestone in stem cell biology and regenerative medicine. The adrenal cortex, the outer layer of the adrenal glands located atop the kidneys, plays a critical role in producing essential hormones like cortisol and aldosterone, which regulate stress responses, metabolism, blood pressure, and electrolyte balance. Disruptions in its development or function lead to serious disorders such as congenital adrenal hyperplasia and primary adrenal insufficiency, affecting thousands worldwide.
This innovation builds on Japan's pioneering role in induced pluripotent stem (iPS) cell technology, first developed by Nobel laureate Shinya Yamanaka at CiRA in 2006. By transforming patient-derived skin or blood cells into iPS cells—pluripotent stem cells capable of differentiating into any cell type—the team created three-dimensional organoids mimicking the layered structure and functional zonation of the fetal adrenal cortex. These zones—the zona glomerulosa, fasciculata, and reticularis—each produce distinct hormones, and their proper formation is vital for endocrine health.
🔬 The Science Behind the Organoid Model
The researchers employed a stepwise differentiation protocol starting from human iPS cells. First, they induced posterior intermediate mesoderm-like cells, then specified adrenocortical progenitors using key signaling pathways like Wnt and BMP. Over several weeks, these progenitors self-organized into organoids exhibiting radial patterning similar to the natural adrenal gland. The model not only replicated anatomical zonation but also demonstrated functional maturity: upon stimulation with adrenocorticotropic hormone (ACTH), the organoids produced cortisol in a dose-dependent manner, mimicking the body's stress response.
Advanced single-cell RNA sequencing revealed dynamic gene expression profiles mirroring fetal development timelines, with markers for steroidogenesis enzymes like CYP11B1 and CYP17A1 expressed in appropriate zones. This level of fidelity surpasses previous two-dimensional cultures or animal models, which fail to capture human-specific zonation dynamics.
Lead Researchers and CiRA's Legacy
Leading the study is Kotaro Sasaki, an associate professor at CiRA with a track record in reproductive and endocrine organoid models. Previously, Sasaki's team reconstituted human fetal adrenal specification using iPS cells, laying the groundwork for this advanced model. Collaborators include Michinori Mayama and other CiRA experts, leveraging the center's expertise in iPS technology.
CiRA, established in 2010, remains the global hub for iPS research, hosting over 300 scientists and producing hundreds of publications annually. This study exemplifies how CiRA's infrastructure—state-of-the-art clean rooms, high-throughput screening facilities, and bioinformatics cores—enables complex organoid engineering. Kyoto University, ranked among Japan's top institutions for life sciences, provides the academic ecosystem fostering such innovations through interdisciplinary collaborations with medical and veterinary schools.
Step-by-Step Differentiation Process
The protocol unfolds in defined stages:
- Day 0-3: iPS cells activated with activin A and FGF2 to form posterior intermediate mesoderm.
- Day 4-7: Induction of SF1-positive adrenocortical progenitors via retinoic acid and BMP4 signaling.
- Day 8-21: Capsule-like structures form, secreting signals for inward migration and zonation.
- Day 22+: Mature organoids respond to ACTH, producing glucocorticoids.
This process yields organoids stable for months, scalable for high-throughput applications. Unlike mouse models, human iPS-derived versions avoid species differences in hormone regulation.
Key Findings and Breakthroughs
The organoids displayed precise functional zonation: outer layers produced mineralocorticoids, middle glucocorticoids, and inner androgens. Stress testing with ACTH confirmed physiological hormone release, with cortisol levels rising 10-fold. Genetic perturbations revealed capsule-derived Wnt signals as essential for progenitor maintenance, offering insights into developmental disorders.
Comparative transcriptomics showed 90% overlap with human fetal adrenal tissue from weeks 8-12 gestation, validating the model's accuracy. The study also highlighted sex-specific differences in androgen production, relevant for conditions like polycystic ovary syndrome.
Clinical Implications for Adrenal Disorders
Primary adrenal insufficiency (Addison's disease) affects 1 in 10,000, requiring lifelong hormone replacement. This model enables personalized iPS-derived transplants, potentially curing the condition. Drug screening identified compounds modulating zonation, promising therapies for Cushing's syndrome (excess cortisol) or hyperaldosteronism (hypertension).
In Japan, where aging populations face rising endocrine issues, this aligns with national regenerative medicine initiatives. CiRA's clinical translation pipeline could fast-track trials, building on approved iPS therapies for Parkinson's and corneal disease.Read the full study in Cell Stem Cell.
Japan's Leadership in Stem Cell Research
Japan invests ¥110 billion annually in regenerative medicine, with CiRA receiving substantial MEXT funding. Over 1,000 clinical iPS trials worldwide stem from Japanese innovations. This study reinforces Kyoto University's position, collaborating with national centers like RIKEN for organoid scaling.
For new academic year students, it highlights career opportunities in bioengineering and endocrinology, with CiRA offering PhD programs and internships.
Challenges and Ethical Considerations
Scalability remains a hurdle; current yields are 20-30% efficient. Long-term maturation to adult-like aldosterone production needs refinement. Ethical issues around iPS sourcing and off-target differentiation are addressed via Japan's strict guidelines.
Safety validation in primates precedes human trials, ensuring no tumorigenesis.
Photo by Marcus Loke on Unsplash
Future Outlook and Global Impact
Next steps include zona glomerulosa modeling for hypertension drugs and patient-specific organoids for precision medicine. International collaborations with UPenn and EU consortia accelerate translation.
In Japanese higher ed, this boosts enrollment in life sciences, positioning universities as innovation hubs amid demographic challenges.
Explore related opportunities at Kyoto University through research positions.
Stakeholder Perspectives
Endocrinologists praise the model for filling gaps in human data. Industry partners eye commercialization, while ethicists emphasize equitable access.